BPS804, another anti-sclerostin fully humanized mAb that has received orphan drug status for the treatment of osteogenesis imperfecta, has demonstrated the ability to reduce myeloma-induced bone loss in preclinical studies [165] although human trials of BPS804 in MM patients have yet to be initiated. Here, SOST is linked to plasma cell myeloma.